ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its Board of Directors has appointed Alexander Tokman as acting Chief Executive Officer to replace Francois Michelon, who stepped down from his role as Chief Executive Officer and as a member of the Board of Directors to pursue other endeavors.

密歇根州安阿伯市——（商业新闻短讯）——热声增强超声波（TAEUS®）的先驱ENDRA Life Sciences Inc.（以下简称“ENDRA”）（纳斯达克：NDRA）今天宣布，其董事会已任命亚历山大·托克曼（Alexander Tokman）为代理首席执行官，以取代弗朗索瓦·米歇伦（Francois Michelon），后者辞去首席执行官的职务，并成为董事会成员，从事其他工作。

The Company also announced the addition to its senior management team of Ziad Rouag as Head of Regulatory and Clinical Affairs and Richard Jacroux as Chief Financial Officer..

该公司还宣布，其高级管理团队将增加Ziad Rouag作为监管和临床事务负责人，Richard Jacroux作为首席财务官。。

Mr. Tokman is a growth-driven executive with 24+ years of cross-functional leadership and P&L management experience centered around the development and commercialization of new technology products and services for Medical Device, Biotech, Consumer Electronics, AI and AgTech markets. He has a demonstrated track record in driving breakthrough revenue growth and valuations for start-ups, micro-caps and Fortune 100 companies and implementing improved strategies and operating mechanisms to accelerate business turnarounds..

托克曼先生是一位以增长为导向的高管，拥有24年以上的跨职能领导和损益管理经验，专注于医疗器械、生物技术、消费电子、人工智能和AgTech市场新技术产品和服务的开发和商业化。他在推动初创公司、微型股和财富100强公司的收入突破性增长和估值，以及实施改进的战略和运营机制以加速业务周转方面拥有良好的业绩记录。。

Prior to ENDRA, he served as a President of a privately held AI/Computer Vision SaaS company and was a CEO-in-Residence at the Allen Institute for Artificial Intelligence (AI2). Mr. Tokman also currently serves as an independent board director for a technology company commercializing a dedicated breast CT imaging platform, and he’s on the board of the American Academy of Thermography, a non-profit organization focused on bringing novel infrared imaging applications for disease diagnosis.

在加入ENDRA之前，他曾担任一家私营AI/计算机视觉SaaS公司的总裁，并担任艾伦人工智能研究所（AI2）的常驻首席执行官。托克曼先生目前还担任一家将专用乳腺CT成像平台商业化的技术公司的独立董事，他是美国热成像学会（American Academy of Thermography）的董事会成员，这是一家非营利性组织，专注于为疾病诊断带来新颖的红外成像应用。

Prior to that, he successfully led an IoT technology microcap for over 12 years and spent over 10 years as an executive with GE Healthcare, where he led several global businesses and successful commercialization of multiple business segments, including PET/CT. Mr. Tokman received both undergraduate and graduate Engineering degrees from University of Massachusetts..

在此之前，他成功领导了物联网技术microcap超过12年，并在GE Healthcare担任高管超过10年，领导了多家全球业务，并成功实现了包括PET/CT在内的多个业务部门的商业化。托克曼先生获得了马萨诸塞州大学的本科和研究生工程学位。。

“As a member of the board, I want to thank Francois for his nine years of faithful service. I am honored to step in and execute on our plan to focus on core regulatory and commercial activities to successfully secure approval and launch our company’s well-patented technology, while exercising a strict fiscal discipline,” said Alexander Tokman, Board Member and acting Chief Executive Officer of ENDRA..

ENDRA董事会成员兼代理首席执行官亚历山大·托克曼（AlexanderTokman）表示：“作为董事会成员，我要感谢弗朗索瓦（Francois）9年来的忠诚服务。我很荣幸能够参与并执行我们的计划，专注于核心监管和商业活动，以成功获得批准并推出公司拥有良好专利的技术，同时实行严格的财务纪律。”。。

“As we refocus our efforts on the critical company deliverables, I am also excited to welcome Ziad and Richard to ENDRA’s management team to help advance our goal of establishing the TAEUS system as a practical detection and monitoring biomarker solution for metabolic health. Ziad, who previously served as a consultant to ENDRA, brings extensive experience in regulatory affairs and will bolster our internal efforts as we move TAEUS through the domestic regulatory process,” stated Tokman.

托克曼表示：“随着我们将工作重点重新放在关键的公司可交付成果上，我也很高兴欢迎齐亚德（Ziad）和理查德（Richard）加入恩德拉（ENDRA）的管理团队，以帮助推进我们建立TAEUS系统作为代谢健康实用检测和监测生物标志物解决方案的目标。齐亚德（Ziad）之前曾担任恩德拉（ENDRA）的顾问，在监管事务方面拥有丰富的经验，并将在我们推动TAEUS通过国内监管程序时加强我们的内部努力。”。

“Richard is a seasoned financial executive and will be an asset to the Company as we grow and scale the business. Irina Pestrikova, formerly Senior Director, Finance, will help to ensure a smooth transition of daily finance operations to Richard, and remain an advisor to the company as she spends more time with her family.”.

“Richard是一位经验丰富的财务主管，随着我们业务的发展和规模的扩大，她将成为公司的资产。前财务高级总监Irina Pestrikova将帮助确保日常财务运营顺利过渡到Richard，并继续担任公司的顾问，因为她与家人相处的时间更长。”。

Ziad Rouag brings to ENDRA more than two decades of experience in the medical device industry as a leader of clinical operations and regulatory affairs for emerging startups and high-growth businesses. Most recently he served as President and Chief Executive Officer of Biomodex, a digital healthcare company.

作为新兴初创公司和高增长企业的临床运营和监管事务的领导者，Ziad Rouag为ENDRA带来了20多年的医疗器械行业经验。最近，他担任数字医疗保健公司Biomodex的总裁兼首席执行官。

Prior to Biomodex, Mr. Rouag served as Vice President of Regulatory and Clinical Affairs at several companies including Juul Labs, PQ Bypass and Altura Medical. Mr. Rouag received both a BS and BA from McGill University, and a J.D. from Rutgers University..

在加入Biomodex之前，Rouag先生曾在Juul Labs、PQ Bypass和Altura Medical等多家公司担任监管和临床事务副总裁。鲁格先生拥有麦吉尔大学的学士和学士学位，以及罗格斯大学的法学博士学位。。

Richard Jacroux has over 20 years of experience in financial management and accounting and began his career at Ernst & Young LLP. He has held the role of Chief Financial Officer at several technology companies, is the founder of Impact Solve, LLC, an accounting and fractional chief financial officer service firm and is an adjunct professor at the University of Washington.

Richard Jacroux拥有20多年的财务管理和会计经验，并在安永会计师事务所（Ernst&Young LLP）开始了他的职业生涯。他曾在多家科技公司担任首席财务官，是Impact Solve，LLC（一家会计和分式首席财务官服务公司）的创始人，也是华盛顿大学的兼职教授。

Mr. Jacroux received a BA in business administration and accounting from the University of Washington, and an MBA from the Kellogg School of Management..

Jacroux先生拥有华盛顿大学工商管理和会计学士学位，以及凯洛格管理学院MBA学位。。

About ENDRA Life Sciences Inc.

关于ENDRA Life Sciences Inc。

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology that characterizes tissue similar to an MRI, but at 1/40th the cost and at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today.

ENDRA Life Sciences是热声增强超声波（TAEUS®）的先驱，这是一种开创性的技术，其特征是组织类似于MRI，但成本仅为患者护理的1/40。TAEUS®旨在与当今全球使用的70多万个超声波系统协同工作。

TAEUS® is initially focused on the non-invasive assessment of fatty tissue in the liver. Steatotic liver disease (SLD, formerly known as NAFLD-NASH) is a chronic liver disease spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including non-invasive visualization of tissue temperature during energy-based surgical procedures.

TAEUS®最初专注于肝脏脂肪组织的非侵入性评估。脂肪变性肝病（SLD，以前称为NAFLD-NASH）是一种慢性肝病谱，影响全球20多亿人，目前尚无实用的诊断工具。除了肝脏之外，ENDRA正在探索TAEUS®的其他几种临床应用，包括基于能量的外科手术过程中组织温度的无创可视化。

For more information, please visit www.endrainc.com..

有关更多信息，请访问www.endrainc.com。。

Forward-Looking Statements

前瞻性声明

All statements in this press release that are not based on historical fact are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” 'anticipate,' “attempt,” 'believe,' 'could,' 'estimate,' 'expect,' “forecast,” “future,” 'goal,' “hope,” 'intend,' 'may,' 'plan,' “possible,” “potential,” “project,” 'seek,' 'should,' 'will,' “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently.

本新闻稿中所有不基于历史事实的声明均为《1933年证券法》第27A节和《1934年证券交易法》第21E节所指的“前瞻性声明”。基于某些假设并描述我们未来计划、战略和期望的前瞻性陈述通常可以通过使用诸如“近似”、“预期”、“尝试”、“相信”、“可能”、“估计”、“预期”、“预测”、“未来”、“目标”、“希望”、“打算”、“可能”、“计划”、“可能”、“潜在”、“项目”、“寻求”、“应该”、“将会”或其他类似术语（包括上述任何一项的负面影响）来识别，尽管一些前瞻性陈述的表达方式有所不同。

Examples of forward-looking statements for ENDRA include, among others: expectations with respect to FDA requirements regarding its clinical trials and de novo submission for its TAEUS liver device; estimates of the timing of future events and anticipated results of its development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches and sales; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; and statements regarding ENDRA’s ability to find and maintain development partners.

ENDRA前瞻性声明的例子包括：对FDA关于其临床试验和从头提交TAEUS肝脏装置的要求的期望；估计未来活动的时间安排及其开发工作的预期结果，包括提交和接收所需监管批准以及产品发布和销售的时间安排；与未来财务状况及预计成本和收入有关的报表；对ENDRA业务战略的期望；以及关于ENDRA寻找和维护发展伙伴的能力的声明。

Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain FDA and other regulatory approvals necessary to sell ENDRA medical devices in c.

前瞻性陈述涉及固有风险和不确定性，这些风险和不确定性可能导致实际结果与前瞻性陈述中的结果产生重大差异，这些因素包括：筹集额外资本以持续经营的能力；能够获得FDA和其他监管机构的批准，以在c销售ENDRA医疗器械。